Balance-sheet StrengthEssentially no debt and a large equity base (~4.4bn) materially reduce financial risk and preserve optionality. Over 2–6 months this supports the firm's ability to fund follow-on investments, absorb portfolio mark-downs, and patiently back exits without forced sales or costly refinancing.
Focused Investment ModelA clear, repeatable model of active ownership in life sciences aligns with structural secular growth in healthcare innovation. Durable value creation comes from hands-on development, staged capital and exits, enabling multi-year appreciation and reducing reliance on short-term market timing.
Portfolio Revenue/gross Margin TailwindsSharp revenue rebound and high gross margin in 2025 suggest operational improvement or successful realizations within holdings. If sustained, this indicates underlying portfolio companies can scale revenue and preserve margins, improving future realizations and long-term NAV growth potential.